High expression of T-cell immunoglobulin and mucin domain-containing protein 3 predicting prognosis of non-small cell lung cancer by promoting monocyte migration

周璐1 陈思通2 李春燕3 黄燕燕3 续力云1*

doi:10.16098/j.issn.0529-1356.2025.06.009

PDF(4565 KB)

Acta Anatomica Sinica ›› 2025, Vol. 56 ›› Issue (6) : 697-703. DOI: 10.16098/j.issn.0529-1356.2025.06.009

High expression of T-cell immunoglobulin and mucin domain-containing protein 3 predicting prognosis of non-small cell lung cancer by promoting monocyte migration

ZHOU Lu¹ CHEN Si-tong² LI Chun-yan³ HUANG Yan-yan³ XU Li-yun^1,3*

Author information +

History +

Abstract

Objective To investigate the expression of T cell immunoglobulin and mucin domaincontaining protein 3 (TIM-3) in peripheral blood mononuclear cells and its relationship with non-small cell lung cancer (NSCLC). Methods TIM-3 expression in monocytes from the peripheral blood of 116 NSCLC patients and 37 healthy volunteers was analyzed via flow cytometry. The expression of TIM-3 in macrophages from tissues was detected via multiplex immunohistochemical staining. Transwell migration experiments were used to detect the migration ability of monocytes. Real-time PCR and ELISA were used to detect the mRNA and protein expression of TIM-3 in monocytes. Results Compared with that in healthy volunteers, TIM-3 expression was upregulated in the peripheral blood monocytes of NSCLC patients (P<0.05). TIM-3 was expressed mainly in macrophages in adjacent tissues and positively correlated with its expression in monocytes in NSCLC patients (P<0.05). Furthermore, high TIM-3 expression promoted monocyte migration in NSCLC patients (P<0.05), and high TIM-3 expression in peripheral blood monocytes indicated poor prognosis(P<0.05). Conclusion TIM-3 expression in peripheral blood monocytes may be a useful indicator of the disease prognosis of NSCLC patients and TIM-3 could be a new target for immunotherapeutic strategies.

Key words

T cell immunoglobulin and mucin domain-containing protein 3

/ Monocyte / Migration ability / Non-small cell lung cancer / Prognosis / Flow cytometry / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHOU Lu CHEN Si-tong LI Chun-yan HUANG Yan-yan XU Li-yun.

High expression of T-cell immunoglobulin and mucin domain-containing protein 3 predicting prognosis of non-small cell lung cancer by promoting monocyte migration

[J]. Acta Anatomica Sinica. 2025, 56(6): 697-703 https://doi.org/10.16098/j.issn.0529-1356.2025.06.009

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6):394-424.

［2］ Kwiecień I, Rutkowska E, Polubiec-Kownacka M,et al. Blood monocyte subsets with activation markers in relation with macrophages in nonsmall cell lung cancer［J］. Cancers (Basel), 2020, 12(9):2513.

［3］ Wang L, Mei X, Liu X, et al. The interleukin-33/ST2 axis enhances lung-resident CD14+ monocyte function in patients with non-small cell lung cancer［J］. Immunol Invest, 2023, 52(1):67-82.

［4］ Qian B Z, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis［J］. Nature, 2011, 475(7355):222-225.

［5］ Hanna RN, Cekic C, Sag D, et al. Patrolling monocytes control tumor metastasis to the lung［J］. Science, 2015, 350(6263):985-990.

［6］ Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease［J］. Nature, 2002, 415(6871):536-541.

［7］ Ausejo-Mauleon I, Labiano S, De La Nava D, et al. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory［J］. Cancer Cell, 2023, 41(11):1911-1926.

［8］ Zhuang X, Zhang X, Xia X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC［J］. Am J Clin Pathol, 2012, 137(6):978-985.

［9］ Shi Y, Wu W, Yang Y, et al. Decreased Tim-3 expression is associated with functional abnormalities of monocytes in decompensated cirrhosis without overt bacterial infection［J］. J Hepatol, 2015, 63(1):60-67.

［10］ Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity［J］. Immunol Rev, 2017, 276(1):97-111.

［11］ Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape［J］. J Immunother Cancer, 2020, 8(1):e000911.

［12］ Datar I, Sanmamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis［J］. Clin Cancer Res, 2019, 25(15):4663-4673.

［13］ Guégan J P, Peyraud F, DadoneMontaudie B, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response［J］. Cell Rep Med, 2024, 5(12):101831.

［14］ Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets［J］. Cancer Cell, 2019, 35(4):588-602.

［15］ Guo Q, Shen S, Guan G, et al. Cancer cell intrinsic TIM-3 induces glioblastoma progression［J］. iScience, 2022, 25(11):105329.

［16］ He X, Peng Y, He G, et al. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer［J］. J Transl Med, 2023, 21(1):717.

［17］ Chen K, Gu Y, Cao Y, et al. TIM3(+) cells in gastric cancer: clinical correlates and association with immune context［J］. Br J Cancer, 2022, 126(1):100-108.

［18］ Palacios L M, Peyret V, Viano ME, et al. TIM3 expression in anaplastic-thyroid-cancer-infiltrating macrophages: An emerging immunotherapeutic target［J］. Biology (Basel), 2022, 11(11):1609.

［19］ Khademi M, Illés Z, Gielen AW, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis［J］. J Immunol, 2004, 172(11):7169-7176.

［20］ Xu L, Huang Y, Tan L, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma［J］. Int Immunopharmacol, 2015, 29(2):635-641.